Rosacea subtypes: A treatment algorithm

Cutis

Volumn 74, Issue 3 SUPPL., 2004, Pages 21-27

  Dahl, Mark V ^a,b,c,d,e  

^a MAYO CLINIC   (United States)

^b Berlex Laboratories   (United States)

^c Galderma Laboratories   (United States)

^d Johnson and Johnson ^*  (United States)

^e Sirius Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; ARTIFICIAL TEAR; AZELAIC ACID; BENZOYL PEROXIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CLINDAMYCIN; CLONIDINE; DOXYCYCLINE; ERYTHROMYCIN; HYDROCORTISONE; ISOTRETINOIN; KETOCONAZOLE; METRONIDAZOLE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PERMETHRIN; PIMECROLIMUS; RETINOIC ACID; SHAMPOO; SULFACETAMIDE; SULFUR; TETRACYCLINE; TOPICAL AGENT; TSUKUBAENOLIDE;

ALGORITHM; CATHETER ABLATION; CLINICAL FEATURE; CLINICAL TRIAL; DEMODEX; DISEASE CLASSIFICATION; ELECTROSURGERY; ERYTHEMA; EYE DISEASE; HUMAN; HYGIENE; INFLAMMATORY DISEASE; PRACTICE GUIDELINE; PRURITUS; REVIEW; ROSACEA; SPECTACLES; TELANGIECTASIA; VALIDATION PROCESS;

ALGORITHMS; COMBINED MODALITY THERAPY; HUMANS; RANDOMIZED CONTROLLED TRIALS; ROSACEA;

EID: 4844231936     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Odom R. The nosology of rosacea. Cutis. 2004;74(suppl 3):5-8.
2. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol 2002;46:584-587.
3. Dahl MV. Pathogenesis of rosacea. Adv Dermatol. 2001;17:29-45.
4. Powell FC. Rosacea and the pilosebaceous follicle. Cutis. 2004;74(suppl 3):9-12.
5. Payne WG, Wang X, Walusimbi M, et al. Further evidence for the role of fibrosis in the pathobiology of rhinophyma. Ann Plast Surg. 2002;48:641-645.
6. Tope WD, Sangueza OP. Rhinophyma's fibrous variant, histopathology and immunohistochemistry. Am J Dermatopathol 1994;16:307-310.
7. Sugarman JH, Fleischer AB Jr, Feldman SR. Off-label prescribing in the treatment of dermatologic disease. J Am Acad Dermatol. 2002;47:217-223.
8. Guyatt GH, Haynes RB, Jaeschke RZ, et al. Users' guides to the medical literature: XXV. evidence-based medicine: principles for applying the users' guides to patient care. Evidence-Based Medicine Working Group. JAMA. 2000;284:1290-1296.
9. Bleicher PA, Charles JH, Sober AJ. Topical metronidazole therapy for rosacea. Arch Dermatol. 1987;123:609-614.
10. Espagne E, Guillaume JC, Archimbaud A, et al. Double-blind study versus excipient of 0.75% metronidazole gel in the treatment of rosacea. Ann Dermatol Venereol. 1993;120:129-133.
11. Jorizzo JL, Lebwohl M, Tobey RE. The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double-blind clinical trial. J Am Acad Dermatol. 1998;39:502-504.
12. Breneman DL, Stewart D, Hevia O, et al. A double-blind multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis. 1998;61:44-47.
13. Nielsen PG. Treatment of rosacea with 1% metronidazole cream: a double-blind study. Br J Dermatol. 1983;108:327-332.
14. Drake L, Leyden J, Lucky A, et al. Evaluation of topical metronidazole cream in rosacea. In: Abstracts of the 55th Annual Meeting of the American Academy of Dermatology; March 21-26, 1997; San Francisco, Calif. Abstract P65.
15. Aronson IK, Rumsfield JA, West DP, et al. Evaluation of topical metronidazole gel in acne rosacea. Drug Intell Clin Pharm. 1987;21:346-351.
16. Veien NK, Christiansen JV, Hjorth N, et al. Topical metronidazole in the treatment of rosacea. Cutis. 1986;38:209-210.
17. Sanchez JL, Somolinos A, Webster G, et al. Combined effect of doxycycline hyclate 20 mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. In: Abstracts of the 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC. Abstract P188.
18. Nielsen PG. A double-blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. Br J Dermatol. 1983;109:63-65.
19. Frucht-Pery J, Sagi E, Hemo I, et al. Efficacy of doxycycline and tetracycline in ocular rosacea. Am J Ophthalmol. 1993;116:88-92.
20. Wilkin JK, DeWitt S. Treatment of rosacea: topical clindamycin versus oral tetracycline. Int J Dermatol. 1993;32:65-67.
21. Marks R, Ellis J. Comparative effectiveness of tetracycline and ampicillin in rosacea, a controlled trial. Lancet. 1971;2:1049-1052.
22. Saihan EM, Burton JL. A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. Br J Dermatol. 1980;102:443-445.
23. Elewski B, Fleischer AB, Pariser DM. A comparison of 15% topical azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular facial rosacea: results of a randomized trial. Arch Dermatol. 2003;139:1444-1450.
24. Hebert AA. Azelaic acid 15% gel reduces the intensity of erythema in patients with moderate, papulopustular facial rosacea: data from two phase 3 trials. In: Abstracts of the 61st Annual Meeting of the American Academy of Dermatology; March 21-26, 2003; San Francisco, Calif. Abstract P55.
25. Kaminester L. Two randomized, vehicle-controlled, double-blind trials of azelaic acid 15% gel in treatment of moderate, papulopustular rosacea: individual experience from a participating center. In: Abstracts of the 61st Annual Meeting of the American Academy of Dermatology; March 21-26, 2003; San Francisco, Calif. Abstract P59.
26. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48:836-845.
27. Bjerke R, Fyrand O, Graupe K. Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulopustular rosacea. Acta Derm Venereol. 1999;79:456-459.
28. Leyden JJ, Grove G, Zerweck C. A double-blind, comparative facial tolerance study of a new 10% sodium sulfacetamide & 5% sulfur aqueous gel (in a 10% urea vehicle) vs. a 10% sodium sulfacetamide & 5% sulfur topical suspension in rosacea & acne subjects with sensitive skin. In: Abstracts of the 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC. Abstract P66.
29. Lebwohl MG, Medansky RS, Russo CL, et al. The comparative efficacy of sodium sulfacetamide 10%/sulfur 5% (Sulfacet-R) lotion and metronidazole 0.75% (MetroGel) in the treatment of rosacea. J Geriatr Dermatol. 1995;3:183-185.
30. Leyden J, Thiboutot D, Shalita A. Blinded photographic review for a double blind, multicenter, placebo-controlled study comparing benzoyl peroxide/clindamycin and placebo for the treatment of rosacea. In: Abstracts of the 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC. Abstract P53.
31. Breneman D. Double blind, multicenter, comparison study of combination benzoyl peroxide/clindamycin or placebo in patients with moderate rosacea. In: Abstracts of the 61st Annual Meeting of the American Academy of Dermatology; March 21-26, 2003; San Francisco, Calif. Abstract P43.
32. Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol. 1994;130:319-324.
33. van Zuuren EJ, Graber MA, Hollis S, et al. Interventions for rosacea (Cochrane Review). In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons.
34. Mark KA, Sparacio RM, Voigt A, et al. Objective and quantitative improvement of rosacea-associated erythema after intense pulsed light treatment. Dermatol Surg. 2003;29:600-604.
35. Jasim ZF, Woo WK, Handley JM. Long-pulsed (6-ms) pulsed dye laser treatment of rosacea-associated telangiectasia using subpurpuric clinical threshold. Dermatol Surg. 2004;30:37-40.
36. Taub AF. Treatment of rosacea with intense pulsed light. J Drugs Dermatol. 2003;2:254-259.
37. Clark SM, Lanigan SW, Marks R. Laser treatment of erythema and telangiectasia associated with rosacea. Lasers Med Sci. 2002;17:26-33.
38. Cassuto DA, Ancona DM, Emanuelli G. Treatment of facial telangiectasias with a diode-pumped Nd:YAG laser at 532 nm. J Cutan Laser Ther. 2000;2:141-146.
39. Bergman J, Rico MJ. Tacrolimus clinical studies for atopic dermatitis and other conditions. Semin Cutan Med Surg. 2001;20:250-259.
40. Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol. 2001;44:995-998.
41. Gulliver WP. Tacrolimus 0.1% ointment is useful in treating rosacea patients with seborrheic dermatitis. In: Abstracts of the 61st Annual Meeting of the American Academy of Dermatology; March 21-26, 2003; San Francisco, Calif. Abstract P90.
42. Wilkin JK. Effect of nadolol on flushing reactions in rosacea. J Am Acad Dermatol. 1989;20:202-205.
43. Wilkin JK. Effect of subdepressor clonidine on flushing reactions in rosacea, change in malar thermal circulation index during provoked flushing reactions. Arch Dermatol. 1983;119:211-214.
44. Erdogan FG, Yurtsever P, Aksoy D, et al. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol. 1998;134:884-885.
45. Millikan LE. Rosacea as an inflammatory disorder: a unifying theory? Cutis. 2004;73(suppl 1):5-8.
46. Hawkins SS, Subramanyan K, Liu D, et al. Cleansing, moisturizing, and sun-protection regimens for normal skin, self-perceived sensitive skin, and dermatologist-assessed sensitive skin. Dermatol Ther. 2004;17:63-68.
47. Bikowski J. The use of therapeutic moisturizers in various dermatologic disorders. Cutis. 2001;68(suppl 5):3-11.
48. Dahl MV, Ross AJ, Schlievert PM. Temperature regulates bacterial protein production: possible role in rosacea. J Am Acad Dermatol. 2004;50:266-272.
49. Jain A, Sangal L, Basal E, et al. Anti-inflammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils. Dermatol Online J. 2004;8:1-8.
50. Odom RB. The subtypes of rosacea: implications for treatment. Cutis. 2004;73(suppl 1):9-14.
51. Del Rosso JQ. A status report on the medical management of rosacea: focus on topical therapies. Cutis. 2002;70:271-275.
52. Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol. 1998;134:679-683.
53. National Rosacea Society. Lasers used to treat some rosacea signs. Available at: http://www.rosacea.org/rr/2001 /summer/article_2.html. Accessed April 20, 2004.
54. Del Rosso JQ, Wolf JE Jr, Leyden J, et al. The treatment of rosacea. Cutis. 2004;73(suppl 1):34-36.
55. Quarterman MJ, Johnson DW, Abele DC, et al. Ocular rosacea, signs, symptoms, and tear studies before and after treatment with doxycycline. Arch Dermatol. 1997;133:89-90.